Phase-2 Study of Tarceva in Patients With Recurrent EGFR Positive and Phosphatase and Tensin Homolog (PTEN) Wild Type Glioblastoma Multiforme and Gliosarcoma
OBJECTIVES:
Primary
- Determine the objective response rate in patients with recurrent epidermal growth
factor receptor (EGFR)-positive and PTEN wild-type glioblastoma multiforme or
gliosarcoma treated with erlotinib hydrochloride.
Secondary
- Assess the response rate in patients who also EGFRVIII mutant and PTEN wild type
glioblastoma multiforme or gliosarcoma.
- Determine the progression-free survival of patients treated with this drug.
OUTLINE: This is an open-label study. Patients are stratified according to concurrent use of
enzyme-inducing antiepileptic drugs (EIAEDs) (yes vs no).
Patients receive oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats
every 4 weeks for up to 1 year in the absence of disease progression or unacceptable
toxicity. Some patients may receive additional erlotinib hydrochloride after 1 year at their
physician's discretion.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Disease Response Measured Objectively by MRI of Brain
Lack of disease progression indicates response to treatment
Every 8 weeks or as indicated
No
Michael D. Prados, MD
Principal Investigator
University of California, San Francisco
United States: Food and Drug Administration
CDR0000492762
NCT00387894
January 2007
March 2009
Name | Location |
---|---|
UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco, California 94115 |